23andMe Holding Co. (ME)
Pre-market:
| Previous close | 0.4671 |
| Open | 0.4820 |
| Bid | 0.4569 x 1600 |
| Ask | 0.5943 x 200 |
| Day's range | 0.4501 - 0.4822 |
| 52-week range | 0.3500 - 2.2100 |
| Volume | |
| Avg. volume | 7,624,308 |
| Market cap | 221.659M |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presentedSOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual Meeting, taking place May 31 - June 4 in Chicago. 23an
- GlobeNewswire
23andMe announces CEO’s intention to pursue a potential take-private
SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and E
- GlobeNewswire
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting ULBP6 23ME-00610, antibody targeting CD200R1: Preclinical data will be presented on targeting the CD200R1 pathway in T cells and natural killer cells using 23ME-00610 as a single agent, or in combination with other anti-tumor therapies SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (
